Virchows Archiv最新文献

筛选
英文 中文
Novel gene fusion discovery in Spitz tumours and its relevance in diagnostics. Spitz肿瘤中的新基因融合发现及其在诊断中的相关性。
IF 3.4 3区 医学
Virchows Archiv Pub Date : 2024-08-01 Epub Date: 2023-09-21 DOI: 10.1007/s00428-023-03649-9
Louis Delsupehe, Thomas Steelandt, Julie Lemahieu, Pieter-Jan Volders, Ellen Geerdens, Severine Berden, Annick Daniels, Guy Froyen, Brigitte Maes
{"title":"Novel gene fusion discovery in Spitz tumours and its relevance in diagnostics.","authors":"Louis Delsupehe, Thomas Steelandt, Julie Lemahieu, Pieter-Jan Volders, Ellen Geerdens, Severine Berden, Annick Daniels, Guy Froyen, Brigitte Maes","doi":"10.1007/s00428-023-03649-9","DOIUrl":"10.1007/s00428-023-03649-9","url":null,"abstract":"<p><p>In addition to morphologic analysis, molecular diagnostic work up of Spitz tumours is often of great value for their accurate diagnosis/classification. Nowadays, next-generation sequencing (NGS) is the predominant screening method in molecular diagnostics. Up to 80% of these melanocytic neoplasms comprise gene fusions as genetic anomalies for which the driver codes for a protein harbouring a kinase domain. However, because of the variety of fusion partners the use of PCR-based targeted enrichment NGS methods is not recommended. We describe a series of four Spitz tumour samples in which distinct gene fusions were detected by hybridisation-based capture NGS (TPM3::ALK, LIMA1::ROS1, LRRFIP2::ROS1 and MYO5A::RET). Two of these fusions are not previously described. All 4 fusions were confirmed by reverse transcription-PCR. These findings demonstrate the need for molecular analysis that can detect unknown fusions in Spitz neoplasms for optimal diagnosis.</p>","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41172350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of CD5/SOX11 double-negative pleomorphic mantle cell lymphoma. CD5/SOX11双阴性套细胞淋巴瘤的鉴定。
IF 3.4 3区 医学
Virchows Archiv Pub Date : 2024-08-01 Epub Date: 2024-05-11 DOI: 10.1007/s00428-024-03813-9
Wen-Yu Chuang, Hung Chang, Lee-Yung Shih, Tsung-Chieh Lin, Chi-Ju Yeh, Shir-Hwa Ueng, Ming-Chung Kuo, Hsiao-Wen Kao, Hsuan Liu, Sheng-Tsung Chang, Chih-Ling Lee, Kuan-Po Huang, Tong-Hong Wang, Yung-Liang Wan, Jau-Song Yu, Chuen Hsueh, Shih-Sung Chuang
{"title":"Identification of CD5/SOX11 double-negative pleomorphic mantle cell lymphoma.","authors":"Wen-Yu Chuang, Hung Chang, Lee-Yung Shih, Tsung-Chieh Lin, Chi-Ju Yeh, Shir-Hwa Ueng, Ming-Chung Kuo, Hsiao-Wen Kao, Hsuan Liu, Sheng-Tsung Chang, Chih-Ling Lee, Kuan-Po Huang, Tong-Hong Wang, Yung-Liang Wan, Jau-Song Yu, Chuen Hsueh, Shih-Sung Chuang","doi":"10.1007/s00428-024-03813-9","DOIUrl":"10.1007/s00428-024-03813-9","url":null,"abstract":"<p><p>Cyclin D1 protein-positive diffuse large B cell lymphoma (DLBCL) has an immunophenotype of CD5(-) cyclin D1(+) SOX11(-), and most cases lack a CCND1 rearrangement and have a gene expression profile of DLBCL. Rarely, cyclin D1 protein-positive DLBCL harbors a CCND1 rearrangement, and some genetic copy number features typical of mantle cell lymphoma (MCL) have been detected. Since gene expression studies have not been performed, whether such CCND1-rearranged cases represent cyclin D1 protein-positive DLBCL or CD5/SOX11 double-negative pleomorphic MCL remains unclear. To date, no cases of CD5/SOX11 double-negative MCL have been reported. In this study, we collected eight cases initially diagnosed as cyclin D1 protein-positive DLBCL, including four with a CCND1 rearrangement and four without. Immunohistochemically, all four CCND1-rearranged cases had >50% of tumor cells positive for cyclin D1 protein, whereas only one (25%) non-rearranged case had >50% positive tumor cells. Analysis of genome-wide copy number, mutational, and gene expression profiles revealed that CCND1-rearranged cases were similar to MCL, whereas CCND1-non-rearranged cases resembled DLBCL. Despite the SOX11 negativity by immunohistochemistry, CCND1-rearranged cases had a notable trend (P = 0.064) of higher SOX11 mRNA levels compared to non-rearranged cases. Here, we show for the first time that CCND1 rearrangement could be useful for identifying CD5/SOX11 double-negative pleomorphic MCL in cases diagnosed as cyclin D1 protein-positive DLBCL. Cases with >50% cyclin D1 protein-positive tumor cells immunohistochemically and higher SOX11 mRNA levels are more likely to have a CCND1 rearrangement, and fluorescence in situ hybridization can be used to detect the rearrangement.</p>","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140909367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Small blue round cell tumor with focal epithelial differentiation harboring a novel YAP1::LEUTX fusion with poor prognosis. 具有局灶上皮分化的小型蓝圆细胞瘤,携带新型 YAP1::LEUTX 融合基因,预后不良。
IF 3.4 3区 医学
Virchows Archiv Pub Date : 2024-08-01 Epub Date: 2024-06-08 DOI: 10.1007/s00428-024-03839-z
Xu-Xi Yang, Feng Gao, Ru Ding, Jia Wei, Xiao-Mei Zhu, Qi-Xing Gong
{"title":"Small blue round cell tumor with focal epithelial differentiation harboring a novel YAP1::LEUTX fusion with poor prognosis.","authors":"Xu-Xi Yang, Feng Gao, Ru Ding, Jia Wei, Xiao-Mei Zhu, Qi-Xing Gong","doi":"10.1007/s00428-024-03839-z","DOIUrl":"10.1007/s00428-024-03839-z","url":null,"abstract":"","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141293741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expression of the tumor antigens NY-ESO-1, tyrosinase, MAGE-A3, and TPTE in pediatric and adult melanoma: a retrospective case control study. 肿瘤抗原 NY-ESO-1、酪氨酸酶、MAGE-A3 和 TPTE 在儿童和成人黑色素瘤中的表达:一项回顾性病例对照研究。
IF 3.4 3区 医学
Virchows Archiv Pub Date : 2024-08-01 Epub Date: 2024-06-18 DOI: 10.1007/s00428-024-03846-0
Stephan Forchhammer, Oltin Tiberiu Pop, Matthias Hahn, Valentin Aebischer, Christian M Seitz, Christopher Schroeder, Alexandra Liebmann, Michael Abele, Hannah Wild, Ewa Bien, Michal Kunc, Dominik T Schneider, Katarina Cuk, Isabel Büttel, Carina Flemmig, Magdalena Peters, Mark Laible, Patrick Brück, Özlem Türeci, Ugur Sahin, Lukas Flatz, Ines B Brecht
{"title":"Expression of the tumor antigens NY-ESO-1, tyrosinase, MAGE-A3, and TPTE in pediatric and adult melanoma: a retrospective case control study.","authors":"Stephan Forchhammer, Oltin Tiberiu Pop, Matthias Hahn, Valentin Aebischer, Christian M Seitz, Christopher Schroeder, Alexandra Liebmann, Michael Abele, Hannah Wild, Ewa Bien, Michal Kunc, Dominik T Schneider, Katarina Cuk, Isabel Büttel, Carina Flemmig, Magdalena Peters, Mark Laible, Patrick Brück, Özlem Türeci, Ugur Sahin, Lukas Flatz, Ines B Brecht","doi":"10.1007/s00428-024-03846-0","DOIUrl":"10.1007/s00428-024-03846-0","url":null,"abstract":"<p><p>Tumor-associated antigens (TAAs) are potential targets for T cell-based immunotherapy approaches in cutaneous melanoma. BNT111, an investigational lipoplex-formulated mRNA-based therapeutic cancer vaccine encoding melanoma TAAs NY-ESO-1, tyrosinase, MAGE-A3, and TPTE, is undergoing clinical testing in adults. Expression of these TAAs in pediatric melanoma is unclear but is a prerequisite for feasibility of this treatment approach in children with melanoma. Our main objective was to characterize expression of those TAAs in pediatric melanomas compared to control cohorts. In this retrospective case control study, protein and transcript expression of NY-ESO-1, tyrosinase, MAGE-A3, and TPTE were analyzed in a cohort of 25 pediatric melanomas, 31 melanomas of young adults, 29 adult melanomas, and 30 benign melanocytic nevi in children using immunohistochemical staining and digital pathology (QuPath) and reverse transcription quantitative PCR. Based on IHC analysis, pediatric melanomas expressed tyrosinase (100.0%), TPTE (44.0%), MAGE-A3 (12.0%), and NY-ESO-1 (8.0%). Young adult melanomas expressed tyrosinase (96.8%), NY-ESO-1 (19.4%), MAGE-A3 (19.4%), and TPTE (3.2%). Adult melanomas expressed tyrosinase (86.2%), MAGE-A3 (75.9%), NY-ESO-1 (48.3%), and TPTE (48.3%). Childhood melanocytic nevi only expressed tyrosinase (93.3%). Expression prevalence of individual TAAs did not differ between subtypes of pediatric melanoma, and no association with prognosis was found. All four TAAs were expressed in pediatric melanoma, albeit NY-ESO-1 and MAGE-A3 to a lesser extent than in adult melanoma. These data support the possibility of investigating vaccines targeting these TAAs for the treatment of pediatric melanoma.</p>","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11329550/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141421138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Round-robin testing for LMO2 and MYC as immunohistochemical markers to screen MYC rearrangements in aggressive large B-cell lymphoma. 将 LMO2 和 MYC 作为免疫组化标记进行循环测试,以筛查侵袭性大 B 细胞淋巴瘤中的 MYC 重排。
IF 3.4 3区 医学
Virchows Archiv Pub Date : 2024-08-01 Epub Date: 2023-06-27 DOI: 10.1007/s00428-023-03584-9
Natalia Papaleo, Fina Climent, Gustavo Tapia, Luis Luizaga, Juan Azcarate, Jan Bosch-Schips, Ana M Muñoz-Marmol, Marta Salido, Carmen Lome-Maldonado, Ivonne Vazquez, Luis Colomo
{"title":"Round-robin testing for LMO2 and MYC as immunohistochemical markers to screen MYC rearrangements in aggressive large B-cell lymphoma.","authors":"Natalia Papaleo, Fina Climent, Gustavo Tapia, Luis Luizaga, Juan Azcarate, Jan Bosch-Schips, Ana M Muñoz-Marmol, Marta Salido, Carmen Lome-Maldonado, Ivonne Vazquez, Luis Colomo","doi":"10.1007/s00428-023-03584-9","DOIUrl":"10.1007/s00428-023-03584-9","url":null,"abstract":"<p><p>Aggressive large B-cell lymphomas (aLBCL) include a heterogeneous group of lymphomas with diverse biological features. One of the approaches to the diagnosis of aLBCL is based on the identification of MYC rearrangements (MYC-R), in addition to BCL2 and BCL6 rearrangements by genetic techniques, mainly fluorescent in situ hybridization (FISH). Because of the low incidence of MYC-R, the identification of useful immunohistochemistry markers to select cases for MYC FISH testing may be useful in daily practice. In a previous work, we identified a strong association between the profile CD10 positive/LMO2 negative expression and the presence of MYC-R in aLBCL and obtained good intralaboratory reproducibility. In this study, we wanted to evaluate external reproducibility. To evaluate whether LMO2 can be a reproducible marker between observers 50 aLBCL cases were circulated among 7 hematopathologists of 5 hospitals. Fleiss' kappa index for LMO2 and MYC were 0.87 and 0.70, respectively, indicating high agreement between observers. In addition, during 2021-2022, the enrolled centers included LMO2 in their diagnostic panels to evaluate prospectively the utility of the marker, and 213 cases were analyzed. Comparing LMO2 with MYC, the group of CD10 positive cases showed higher specificity (86% vs 79%), positive predictive value (66% vs 58%), likelihood positive value (5.47 vs 3.78), and accuracy (83% vs 79%), whereas the negative predictive values remained similar (90% vs 91%). These findings place LMO2 as a useful and reproducible marker to screen MYC-R in aLBCL.</p>","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11329383/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9680786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel dual gene fusions identified in a late pulmonary metastasis of an infantile fibrosarcoma-like tumor. 在婴儿纤维肉瘤样肿瘤晚期肺转移中发现新的双基因融合。
IF 3.4 3区 医学
Virchows Archiv Pub Date : 2024-07-30 DOI: 10.1007/s00428-024-03882-w
Karen Schoedel, Shaymaa Hegazy, Megan L Zilla, Jason Chang, Benjamin A Nacev
{"title":"Novel dual gene fusions identified in a late pulmonary metastasis of an infantile fibrosarcoma-like tumor.","authors":"Karen Schoedel, Shaymaa Hegazy, Megan L Zilla, Jason Chang, Benjamin A Nacev","doi":"10.1007/s00428-024-03882-w","DOIUrl":"10.1007/s00428-024-03882-w","url":null,"abstract":"","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141793628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Morphological and immunohistochemical evaluation in distinguishing post-radiotherapy serous-like endometrial change (PoRSEC) and serous endometrial intraepithelial carcinoma (SEIC). 区分放疗后浆液性样子宫内膜病变(PoRSEC)和浆液性子宫内膜上皮内癌(SEIC)的形态学和免疫组化评估。
IF 3.4 3区 医学
Virchows Archiv Pub Date : 2024-07-30 DOI: 10.1007/s00428-024-03818-4
Damiano Arciuolo, Giulia Scaglione, Antonio Travaglino, Nicoletta D'Alessandris, Angela Santoro, Frediano Inzani, Belen Padial Urtueta, Stefania Sfregola, Antonio Raffone, Caterina Fulgione, Michele Valente, Roberta Benvenuto, Federica Cianfrini, Gian Franco Zannoni
{"title":"Morphological and immunohistochemical evaluation in distinguishing post-radiotherapy serous-like endometrial change (PoRSEC) and serous endometrial intraepithelial carcinoma (SEIC).","authors":"Damiano Arciuolo, Giulia Scaglione, Antonio Travaglino, Nicoletta D'Alessandris, Angela Santoro, Frediano Inzani, Belen Padial Urtueta, Stefania Sfregola, Antonio Raffone, Caterina Fulgione, Michele Valente, Roberta Benvenuto, Federica Cianfrini, Gian Franco Zannoni","doi":"10.1007/s00428-024-03818-4","DOIUrl":"https://doi.org/10.1007/s00428-024-03818-4","url":null,"abstract":"<p><p>Uteri from women undergoing chemoradiotherapy (CRT) may show reactive atypia which may mimic serous endometrial intraepithelial carcinoma (SEIC). We aimed to assess the prevalence and morphological/immunohistochemical features of post-radiotherapy serous-like endometrial changes (PoRSEC) in women undergone CRT for locally advanced cervical cancer, with a focus on the differential diagnosis with SEIC. Consecutive patients with locally advanced cervical cancer undergone CRT between 2011 and 2018 were reviewed. Endometrial histological specimens were assessed for the presence of PoRSEC. Twenty-two cases of SEIC were included for comparison. Immunohistochemistry for p53, p16, and Ki67 was performed. Out of 244 reviewed patients, 36 (14.7%) showed PoRSEC. The degree of nuclear atypia was similar between PoRSECs and SEIC. However, a papillary architecture with areas of confluent papillae was only observed in SEIC. SEIC cases showed a high mitotic activity as opposed to PoRSEC cases. The expression of p53 was aberrant in all SEICs but in none of the PoRSECs; however, 13/36 PoRSECs showed p53 positivity in most tumor cells, potentially mimicking a mutation pattern. A block-type p16 expression was observed in all SEICs and in 16/36 PoRSECs. Mean Ki67 expression was 26.9% in SEIC (range 5-70%) and 8.16% in PoRSEC (range 5-35%). While SEIC showed sharp morphological and immunohistochemical demarcation, PoRSEC were more heterogenous and merged imperceptibly with normal endometrium. In conclusion, PoRSEC may mimic SEIC both morphologically and immunohistochemically. However, a papillary architecture with cytological demarcation is typically observed in SEIC but not in PoRSEC.</p>","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141793627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Human epidermal growth factor 2 (HER2) amplification in uterine serous carcinoma: an analysis of prognosis and immune microenvironment. 子宫浆液性癌中人表皮生长因子 2 (HER2) 扩增:预后和免疫微环境分析。
IF 3.4 3区 医学
Virchows Archiv Pub Date : 2024-07-29 DOI: 10.1007/s00428-024-03874-w
Ying Shao, Ruiyi Xu, Haiyan Shi, Lei Ye, Hui Wang, Bingjian Lu
{"title":"Human epidermal growth factor 2 (HER2) amplification in uterine serous carcinoma: an analysis of prognosis and immune microenvironment.","authors":"Ying Shao, Ruiyi Xu, Haiyan Shi, Lei Ye, Hui Wang, Bingjian Lu","doi":"10.1007/s00428-024-03874-w","DOIUrl":"https://doi.org/10.1007/s00428-024-03874-w","url":null,"abstract":"<p><p>Uterine serous carcinoma (USC) is a biologically aggressive subtype of endometrial cancer. Anti-human epidermal growth factor receptor 2 (HER2) therapy has demonstrated its promising effects on HER2-positive USC. However, data on prognostic relevance and immune microenvironment are limited in HER2-positive USC. This study aimed to determine the clinicopathologic features, prognosis, and the immune microenvironment trait in HER2 status in USC. We applied immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and multi-color immunofluorescence to investigate HER2 expression and amplification, PD-L1 expression, and tumor infiltration lymphocytes (TIL) in 77 USC (61 pure and 16 mixed-type USC). HER2 IHC 1 + , 2 + , and 3 + were found in 26, 18, and 10 USC, respectively. HER2 staining frequently had an incomplete membrane (basolateral or \"U\"-shaped) pattern. Twenty-three cases (23/54, 42.6%) showed an intra-tumor heterogeneous staining. HER2 amplification was present in 16/77 (20.8%) USC. HER2 amplification was significantly associated with deep myometrial invasion (> 1/2), and increased intra-epithelial and stromal density of CD20 + or CD8 + TIL (all P < 0.05), but not with USC subtypes (pure versus mixed-type), PD-L1 expression, CD4 + TIL, CD68 + histiocytes, or the CD4 + /CD8 + ratio (p > 0.05). HER2 amplification was associated with poor overall and progression-free survival in USC, but lost the prognostic significance on multivariate analysis. We concluded that HER2 amplified USC had adverse clinical outcomes, but showed the potential active immune microenvironment. Our findings raised the possibility of the combined anti-HER2 and immunotherapy for HER2-positive USC in the future.</p>","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141789059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ETV6::ABL1 fusion: from overlooked minor clone in myeloproliferative neoplasm to major player in leukemic transformation ETV6::ABL1 融合:从骨髓增生性肿瘤中被忽视的小克隆到白血病转化中的主要角色
IF 3.5 3区 医学
Virchows Archiv Pub Date : 2024-07-27 DOI: 10.1007/s00428-024-03881-x
Hyun-Woo Lee, Min-Seung Park, Boram Kim, Chul Won Jung, Hee-Jin Kim, Hyun-Young Kim
{"title":"ETV6::ABL1 fusion: from overlooked minor clone in myeloproliferative neoplasm to major player in leukemic transformation","authors":"Hyun-Woo Lee, Min-Seung Park, Boram Kim, Chul Won Jung, Hee-Jin Kim, Hyun-Young Kim","doi":"10.1007/s00428-024-03881-x","DOIUrl":"https://doi.org/10.1007/s00428-024-03881-x","url":null,"abstract":"","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":null,"pages":null},"PeriodicalIF":3.5,"publicationDate":"2024-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141769898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to: Abstracts  : 32nd Congress of the ESP and XXXIII International Congress of the IAP. 更正:摘要:第 32 届 ESP 大会和第 XXXIII 届 IAP 国际大会。
IF 3.4 3区 医学
Virchows Archiv Pub Date : 2024-07-23 DOI: 10.1007/s00428-024-03871-z
{"title":"Correction to: Abstracts  : 32nd Congress of the ESP and XXXIII International Congress of the IAP.","authors":"","doi":"10.1007/s00428-024-03871-z","DOIUrl":"https://doi.org/10.1007/s00428-024-03871-z","url":null,"abstract":"","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141749166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信